Emerging Strategies for More Cost-Effective Product Development in the NASH Indication
Chiltern’s Randy Anderson, PhD, therapeutic area leader for diseases of endocrinology and metabolism, explores new strategies and technologies for managing the complexity of nonalcoholic steatohepatitis (NASH) product studies while maintaining a cost-effective partnership with your CRO. This presentation was originally given at OCT West Coast in Burlingame, CA, February 22, 2017.